AstraZeneca's experimental COPD drug aced late-stage trials, boosting blockbuster sales hopes Sep 08, 2026 · Cris Tolomia The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S. approval expected in early 2027 Read more »
.png?branch=production)
![Prediction: This Pipeline Stock's Payout Will Grow Faster Than Chevron's [or Exxon's] Over the Next 5 Years](https://media.zenfs.com/en/motleyfool.com/ce9f8ee3e848bda8f77a44da7292e1e4.jpg)
